Amgen has announced a $200 million investment to establish a technology and innovation center in Hyderabad, India. The facility, spanning approximately 524,000 square feet in RMZ Tower 110 of Spire, will focus on artificial intelligence and data science applications in drug discovery and clinical trials. The center is expected to employ around 2,000 professionals by the end of the year, with 300 already on board.
The Hyderabad facility aims to enhance Amgen’s digital capabilities, supporting drug development and regulatory processes more efficiently. This expansion aligns with India’s reputation as a hub for biotechnology and life sciences. The investment also reflects the growing technological partnership between the United States and India.
The center’s inauguration was attended by Telangana Chief Minister A. Revanth Reddy, who highlighted Hyderabad’s position as a global hub for innovation and technology in the biotech and life sciences sectors.
Amgen’s commitment to expanding its presence in India is further demonstrated by its plans to make additional significant investments in the coming years. The Hyderabad center will play a crucial role in accelerating research, regulatory review, and the availability of new treatments worldwide.
This development comes as India and the United States engage in discussions to resolve tariff disputes and promote technology collaboration, exemplified by initiatives like the U.S.-India trust initiative. The BioAsia conference in Hyderabad will further explore these developments, featuring pharmaceutical industry leaders.
Amgen’s investment in Hyderabad underscores the city’s growing prominence in the global biotechnology landscape and its strategic importance in the company’s global operations.